Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Boyle

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Frontiers in Psychiatry|March 27, 2023
A hidden pandemic? An umbrella review of global evidence on mental health in the time of COVID-19Marlee Bower, Scarlett Smout, Amarina Donohoe-Bales, et al.
Pharmacy (Basel, Switzerland)|July 18, 2020
Practice Transformation Driven through Academic PartnershipsRenee Robinson, Cara Liday, Anushka Burde, et al.
Pediatric Research|August 30, 2024
Post COVID-19 conditions in an Australian pediatric cohort, 3 months following a Delta outbreakPhilip N Britton, Rebecca Burrell, Emily Chapman, et al.
Plos One|October 17, 2023
Mental health and wellbeing outcomes of youth participation: A scoping review protocolMarlee Bower, Amarina Donohoe-Bales, Andre Quan Ho Nguyen, et al.
The Lancet. Digital Health|April 26, 2024
Effectiveness of a universal, school-based, online programme for the prevention of anxiety, depression, and substance misuse among adolescents in Australia: 72-month outcomes from a cluster-randomised controlled trialMaree Teesson, Louise Birrell, Tim Slade, et al.
Plant Biotechnology Journal|July 7, 2015
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plantsJulian K-C Ma, Jürgen Drossard, David Lewis, et al.
The Lancet. Haematology|October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised studyMeletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Frontiers in Psychiatry|March 27, 2023
A hidden pandemic? An umbrella review of global evidence on mental health in the time of COVID-19Marlee Bower, Scarlett Smout, Amarina Donohoe-Bales, et al.
Pharmacy (Basel, Switzerland)|July 18, 2020
Practice Transformation Driven through Academic PartnershipsRenee Robinson, Cara Liday, Anushka Burde, et al.
Pediatric Research|August 30, 2024
Post COVID-19 conditions in an Australian pediatric cohort, 3 months following a Delta outbreakPhilip N Britton, Rebecca Burrell, Emily Chapman, et al.
Plos One|October 17, 2023
Mental health and wellbeing outcomes of youth participation: A scoping review protocolMarlee Bower, Amarina Donohoe-Bales, Andre Quan Ho Nguyen, et al.
The Lancet. Digital Health|April 26, 2024
Effectiveness of a universal, school-based, online programme for the prevention of anxiety, depression, and substance misuse among adolescents in Australia: 72-month outcomes from a cluster-randomised controlled trialMaree Teesson, Louise Birrell, Tim Slade, et al.
Plant Biotechnology Journal|July 7, 2015
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plantsJulian K-C Ma, Jürgen Drossard, David Lewis, et al.
The Lancet. Haematology|October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised studyMeletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
Pageof 4